Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04527887
Other study ID # STUDY00000084
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date September 4, 2020
Est. completion date December 2024

Study information

Verified date June 2023
Source Tufts Medical Center
Contact Nancy Gee, MPH
Phone 617-636-5489
Email ngee@tuftsmedicalcenter.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective, single-center, randomized, double-masked, parallel comparison, sponsored study seeks to investigate the efficacy of Intracanalicular dexamethasone Insert (IDI) on ameliorating the signs and symptoms of dry eye disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 54
Est. completion date December 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of Dry Eye Disease - Objective Signs (Schirmer's II test <10 mm at 5 min; Tear Break-Up time (TBUT) of <10 seconds in 1 eye; corneal fluorescein staining of .=4 in at least 1 eye; conjunctival lissamine green staining of the nasal and temporal conjunctive >=4 in at least 1 eye) - Ocular inflammation presence confirmed by In-Vivo Confocal Microscopy Exclusion Criteria: - History of Diabetes - History of ocular surgery, corneal infection, or corneal injury within the last 3 months - Active ocular allergies - Active ocular infection - Allergic to benzalkonium chloride

Study Design


Intervention

Drug:
Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)
Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of postsurgical inflammation and pain associated with ocular surgery.
Other:
ProLong™ collagen plugs
The long term synthetic punctal plug is composed of an absorbable copolymer material and measures 0.4mm in diameter and 2.0mm in length.

Locations

Country Name City State
United States Tufts Medical Center Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Tufts Medical Center Ocular Therapeutix, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in ocular inflammation As measured by change to dendritic cell density and ocular redness Change from Baseline one month after intracanalicular insert implantation or punctal plug
Secondary Clinical Parameter: Ocular Surface Disease Index (OSDI) 12-item scale; score ranges from 0 to 100 and is calculated by the sum of the scores for all 12 questions answered multiplied by 100, which is divided by the total number of questions answered times four Change from Baseline one month after intracanalicular insert implantation or punctal plug
Secondary Clinical Parameter: Ocular Pain Assessment Survey (OPAS) 32-questions, 8-domain questionnaire using numerical rating scales to assess eye pain intensity (worse eye) in the past 24 hours and 2 weeks (worst, least and average pain intensity), frequency of eye and non-eye pain (past 24 hours and 2 weeks), non-eye pain intensity (past 24 hours and 2 weeks), impact on QoL, pre-occupation with eye and non-eye pain, aggravating factors and associated factors.) Change from Baseline one month after intracanalicular insert implantation or punctal plug
Secondary Clinical Parameter: Symptom Assessment in Dry Eye scores (SANDE) Score is calculated by multiplying the frequency of symptoms score with the severity of symptoms score and obtaining the square root. Change from Baseline one month after intracanalicular insert implantation or punctal plug
Secondary Clinical Parameter: Tear Break Up Time (TBUT) The standard TBUT measurement will be performed by dropping a fluorescein drop to the inferior tarsal conjunctiva and waiting 30 seconds. After several blinks, the tear film will be examined. The time lapse between the last blink and the appearance of the first randomly distributed dark discontinuity in the fluorescein stained tear film will be measured three times and the mean value of the measurements will be calculated. Change from Baseline one month after intracanalicular insert implantation or punctal plug
Secondary Clinical Parameter: Conjunctival staining Grading of conjunctival lissamine green staining will be performed after 1 minutes of application of a lissamine green drop. Staining will be graded using the National Eye Institute (NEI) grading scheme, with a total range of 0-18. Change from Baseline one month after intracanalicular insert implantation or punctal plug
Secondary Clinical Parameter: Corneal staining with fluorescein Corneal fluorescein staining will be performed after 2 minutes of application of a fluorescein drop. Staining will be graded using the National Eye Institute (NEI) grading scheme, with a total range of 0-15. Change from Baseline one month after intracanalicular insert implantation or punctal plug
Secondary Clinical Parameter: Schirmer II test Aqueous tear production will be measured by the length in millimeters that the strip wets during 5 minutes. Change from Baseline one month after intracanalicular insert implantation or punctal plug
See also
  Status Clinical Trial Phase
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A
Completed NCT01718028 - The Effect of SYSTANE® BALANCE on Tear Film Break Up Time in Dry Eye Subjects N/A